Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 mRNA-electroporated dendritic-cell vaccine plus adjuvant temozolomide in newly diagnosed glioblastoma
2014-001098-15Phase 2Active
- Sponsor
- Antwerp University Hospital
- Start
- Jul 2015
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 mRNA-electroporated dendritic-cell vaccine in glioblastoma (GBM), sponsored by Antwerp University Hospital. Started Jul 2015; status: active.
02
Drugs
WT1 mRNA-electroporated dendritic-cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2014-001098-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001098-15.